U.S. Hospitality Stock News

NYSE:HR
NYSE:HRHealth Care REITs

How Attractive Is Healthcare Realty Trust After Its Recent Quarterly Results in 2025?

If you're considering what to do with your Healthcare Realty Trust shares, or perhaps thinking about making a move, you're not alone. The stock has been making waves, sometimes subtle, sometimes more noticeable. Over just the past week, there was a minimal dip of -0.1%, and the past month has seen a slightly larger decline of -1.8%. Yet, zooming out, things look far sunnier: Healthcare Realty Trust is up 7.7% so far this year and a solid 9.5% over the last twelve months. Of course, anyone who...
NYSE:SPNT
NYSE:SPNTInsurance

Is SiriusPoint Still Attractive After Three-Year 259% Rally and Industry Tailwinds in 2025?

If you’ve been tracking SiriusPoint’s stock, you know this isn’t one of those sleepwalking tickers. Whether you’re eyeing that impressive 259.4% gain over the last three years or sizing up this year’s 15.8% return, SiriusPoint has certainly kept things interesting for shareholders. Even with a slight dip over the last month, it’s clear that investors are reassessing the company’s growth prospects and its risk, potentially setting up for the next big move. Much of the recent momentum seems...
NasdaqGM:SKYE
NasdaqGM:SKYEBiotechs

A Look at Skye Bioscience (SKYE) Valuation After Its Phase 2a Nimacimab Topline Update

Skye Bioscience (SKYE) has scheduled a special call to present topline data from its Phase 2a clinical trial of Nimacimab, focusing on both monotherapy and combination treatment. Updates like these frequently shape investor sentiment around development-stage biotech stocks. See our latest analysis for Skye Bioscience. Skye Bioscience’s latest topline clinical update arrives after a period of muted share price action. Its stock closed at $1.90 and has shown minimal momentum over recent months...
NYSE:SHCO
NYSE:SHCOHospitality

Is Soho House a Hidden Opportunity After 69% Share Price Surge and Improved Profit Outlook?

If you are looking for the next move on Soho House & Co stock, you have probably noticed its eye-catching trajectory. This is not a slow and steady story, but one with dramatic swings and the kind of big numbers that spark conversation. Just over the past year, Soho House & Co’s shares have surged 69.1%. If you stretch that lens out to three years, we are talking 114.5% growth, which is well beyond what most lifestyle or hospitality names can boast. Even in recent months, the stock has kept...
NasdaqGS:RUSH.A
NasdaqGS:RUSH.ATrade Distributors

Evaluating Rush Enterprises Shares After Recent 14% Slide and Truck Market Uncertainty

If you have been watching Rush Enterprises, you may be asking yourself whether now is the moment to buy, hold, or move on. The stock price has slipped by 7.3% in the past week and it is down more than 14% over the last month. Year to date, shares have shed 8.8%. On a longer horizon, however, Rush Enterprises has quietly put together an impressive run, climbing 70.8% over three years and more than doubling investors’ money over five years with a 114.6% gain. That kind of return turns heads,...
NasdaqGS:AMD
NasdaqGS:AMDSemiconductor

Dow Futures Slip Amid US, Europe Political Uncertainty

The Morning Bull - US Market Morning Update Tuesday, Oct, 7 2025 US stock futures are moving lower ahead of the open as persistent political uncertainty in both the US and Europe weighs on sentiment. With the US government shutdown showing no signs of resolution and French bond yields near multi-year highs because of fiscal and leadership gridlock, investors are focused on how these tensions could drive volatility and put pressure on areas of the market most sensitive to economic momentum and...
NYSE:BEPC
NYSE:BEPCRenewable Energy

Does Analyst Optimism on Brookfield Renewable (BEPC) Reveal Deeper Strengths in Its Growth Strategy?

RBC Capital has reiterated its positive outlook for Brookfield Renewable, highlighting enhanced growth visibility and strong confidence in the company's long-term expansion plans following recent operational results. Despite reporting lower-than-expected Q2 2025 profits, Brookfield Renewable saw a 10% year-over-year rise in Funds From Operations, driven largely by its hydropower and distributed energy businesses. We'll examine how analyst confidence in Brookfield Renewable's operational...
NasdaqGS:SENS
NasdaqGS:SENSMedical Equipment

Senseonics Holdings (SENS) Is Up 27.7% After Q3 Revenue Surge and Record New Patient Growth Has the Bull Case Changed?

On October 6, 2025, Senseonics Holdings announced preliminary unaudited revenue for the third quarter ended September 30, reporting approximately US$8.1 million, an increase of 91% over the same period in 2024, primarily attributed to roughly 160% new patient growth in the U.S. This upturn in both revenue and new patient adoption highlights more robust market traction, suggesting a potential acceleration in demand for the company’s continuous glucose monitoring systems. We’ll now explore how...
NYSE:KNF
NYSE:KNFBasic Materials

Is Knife River’s Share Slide Justified After $500 Million Infrastructure Contract Win?

If you're standing at the crossroads of what to do with your Knife River shares or thinking of putting some capital to work, you're not alone. Knife River’s recent performance has grabbed the attention of both cautious investors and opportunists, sparking plenty of debate on whether the current price fairly reflects the company’s long-term prospects. Knife River's stock price has seen a difficult stretch lately. Down 3.9% in the last week, 11.6% in the last month, and a hefty 29.2%...
NasdaqGM:ACIU
NasdaqGM:ACIUBiotechs

AC Immune (NasdaqGM:ACIU): Exploring Valuation Following Promising Phase 1b/2a Alzheimer’s Data Publication

AC Immune (NasdaqGM:ACIU) just shared peer-reviewed data from its Phase 1b/2a trial of ACI-35.030, an active immunotherapy targeting Tau in early Alzheimer's, developed with Janssen. The findings highlight a rapid and sustained antibody response as well as a clean safety profile. See our latest analysis for AC Immune. With this encouraging clinical update, AC Immune is starting to turn heads, especially as the company’s latest innovation underscores its growing potential in Alzheimer’s...
NYSE:IPG
NYSE:IPGMedia

How Bayer’s Global Creative Agency Deal Has Changed Interpublic Group’s (IPG) Investment Story

In September 2025, Bayer’s Consumer Health division announced it had selected Interpublic Group as its exclusive global creative, production, and media agency partner for iconic self-care brands including Aspirin and Claritin. This partnership signals Bayer’s commitment to integrated marketing powered by GenAI for both global consistency and tailored local consumer engagement. We'll review how IPG’s appointment as Bayer’s lead global partner could strengthen its client portfolio and...
NasdaqGS:CRDO
NasdaqGS:CRDOSemiconductor

Three High Growth Stocks With Strong Insider Confidence

As the Nasdaq and S&P 500 reach new closing highs, buoyed by significant tech deals and a resilient market response to the ongoing U.S. government shutdown, investors are increasingly focused on stocks that demonstrate both robust growth potential and strong insider confidence. In this thriving market environment, companies with high insider ownership often signal enduring trust in their long-term prospects, making them compelling considerations for those looking to align with informed...
NYSE:APAM
NYSE:APAMCapital Markets

Top Dividend Stocks Featuring Artisan Partners Asset Management

As the U.S. stock market continues to reach new heights, with the Nasdaq and S&P 500 posting record closing highs, investors are increasingly seeking opportunities that offer both growth potential and reliable income streams. In this vibrant economic landscape, dividend stocks stand out as a compelling choice for those looking to balance risk and reward while capitalizing on consistent returns.